Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of November 2016, with a specific announcement date of November 2, 2016. The filing serves to notify shareholders and warrant holders of upcoming special meetings scheduled for December 8, 2016, at the company's offices in Petach-Tikva, Israel.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural notice regarding corporate governance meetings and does not contain financial statements or performance data.
Material Changes
No material changes to financial performance or operations are reported in this filing. The primary event is the scheduling of four distinct special meetings to be held on the same day:
- Special Meeting of Shareholders at 4:00 p.m. Israel time.
- Special Meeting of Series 10 Warrant Holders at 4:30 p.m. Israel time.
- Special Meeting of Series 11 Warrant Holders at 4:45 p.m. Israel time.
- Special Meeting of Series 12 Warrant Holders at 5:00 p.m. Israel time.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, or specific risks. It references a Notice and Proxy Statement (Exhibit 99.1) which describes the proposal to be voted upon, but the specific details of the proposal are not included in the text of this Form 6-K. The filing incorporates by reference into various Registration Statements on Form F-3.
Key Facts for Investor Verification
- Verify the specific proposal to be voted on by reviewing the attached Notice and Proxy Statement (Exhibit 99.1).
- Confirm the record date for eligibility to vote at the December 8, 2016 meetings.
- Review the voting procedures for ordinary shares versus Series 10, 11, and 12 Warrants as detailed in the respective proxy cards (Exhibits 99.2 through 99.5).
- Note that this filing does not disclose financial results; investors should refer to the most recent Form 20-F or quarterly reports for financial data.